All News

Reducing harm from omitted & delayed Parkinsons Disease medication

Medicines management is crucial in the care of the patient with Parkinson’s Disease (PD) when they are admitted to hospital, either electively or in an emergency. Missed or delayed doses can impair patients’ swallow, increase their risk of aspiration, render them immobile and prone to falls and fractures, and at worst, progress to Neuroleptic Malignant Syndrome, which can lead to coma or death.

 IMSN Safety Alert on Reducing Harm from Omitted & Delayed Parkinson's Disease Medications in Hospital

 

Safety Alert: Rhabdomyolysis with Fusidic Acid and Statins

Rhabdomyolysis is a rare complication of statin monotherapy. However the risk of rhabdomyolysis is much higher when patients are exposed to the combination of systemic fusidic acid (as fusidic acid hemihydrate/sodium fusidate; hereafter referred to simply as 'fusidic acid') and a statin, compared with exposure to a statin alone.

Click here to read the alert

Risks associated with High-Strength Insulin Preparations

Insulin is a high risk drug which has the potential to cause serious harm if it is not used correctly.1 Until recently, all insulin available on the European market contained 100 units / mL. A high-strength insulin is one which contains insulin at a concentration of more than the standard 100 units / mL.2 These high-strength insulin products may contain, for example, 200 units / mL or 300 units / mL. There is a potential for harm if these products are not prescribed, dispensed, and administered properly.

Click here to read the alert